Human Rabies Immune Globulin (Rablg)
HyperRAB®     Supplier: Grifols Canada Inc.

INDICATIONS: A
• Human Rabies Immune Globulin (Rablg) is used for Rabies Post-Exposure Prophylaxis (RPEP) as determined by the Medical Health Officer. Consultation is available to Medical Health Officers with Communicable Diseases and Immunization Service (CDIS), BCCDC.
• Rablg should be given in conjunction with the 1st dose of rabies vaccine. Rabies vaccine and Rablg must be administered with separate needles and syringes at separate anatomical sites.
• If a rabies vaccine series has been started or completed elsewhere, and it was not given in accordance with the current WHO standards, administer Rablg (on day 0) in conjunction with the 1st dose of another full series of rabies vaccine. See Communicable Disease Control Manual, Chapter 1: Rabies, section 4.2.1.

DOSES AND SCHEDULE: B
• The recommended maximum dosage for children and adults is the same: 20 IU/kg of body weight.
• The maximum dose of HyperRAB® is calculated as:
  \[ \text{[20 IU/kg x weight in kg]} = \text{___ mL.} \]
  \[ 300 \text{ IU/mL} \]
  Do not exceed the recommended dose due to interference with active antibody production.

ADMINISTRATION:
• As per the Interim Guidelines for the Use of RIG in BC issued on July 19, 2019, Rablg should only be used to infiltrate the wound or the exposed area. The administration of additional Rablg by intramuscular injection is no longer recommended. Depending on site, size and extent of wound(s), the actual volume of Rablg may be less than the recommended maximum dose. Consult with local Medical Health Officer to determine actual dose to be administered.
• HyperRAB® is supplied in 1 mL vials at a concentration of 300 IU/mL. Infiltrate as much Rablg as possible up to the maximum volume calculated above deep into and around the wound(s) in order to neutralize the virus.
  o When more than one wound site exists, each site should be infiltrated with a portion of the Rablg, using a separate syringe and needle for each infiltration.
  o If there are extensive wounds, where the calculated dose of Rablg (by weight) is not adequate in volume to infiltrate all wounds, the HyperRAB® dose may be diluted with an equal volume of dextrose, 5% (D5W) in water to create an adequate volume to infiltrate all wounds. Do not dilute with normal saline.
  o Infiltration of wounds in some anatomical sites (finger tips) must be carried out with care in order to avoid increased pressure in the tissue compartment (compartment syndrome).

---

A Since vaccine induced antibodies begin to appear within 1 week, there is no value in administering Rablg more than 7 days after initiation of vaccine.
B When notification of an exposure is delayed, RPEP may be started as late as 6 or more months after an exposure.
Human Rabies Immune Globulin (RabIg)
HyperRAB®     Supplier: Grifols Canada Inc.

ADMINISTRATION (continued):
• RabIg contains no preservatives. Vials are single dose use. Once entered, discard any unused contents.

BOOSTER DOSES:
None.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
None.

PRODUCT COMPONENTS:
Potential allergens: none.
Other components: glycine.

PRECAUTIONS:
• Give RabIg with caution (i.e., in an emergency room setting) if the client has a history of anaphylactic reaction following receipt of any immune globulin product or a history of anaphylactic reaction to any component of HyperRAB® (assess risks versus benefits).
• Human Ig products are among the safest blood-derived products available. The method of preparation includes one or more steps that exclude or inactivate hepatitis B, C and HIV; therefore the risk of transmission is extremely low. However, it is possible, that unknown infectious agents may be present in such products. The benefits of use of rabies immunoglobulin after exposure to rabies far outweigh the theoretical risk of receipt of a blood product.
• Persons with IgA deficiency have the potential for developing antibodies to IgA and could have an anaphylactic reaction to subsequent blood products that contain IgA. Therefore, RabIg should only be given to such persons if the expected benefits outweigh the risks, and should be administered in an emergency room setting.

SPECIAL CONSIDERATIONS:
• Document receipt of RabIg in the client’s electronic record (e.g., Panorama, PARIS) and/or chart. The following information must be recorded: trade name of product, date, lot number, dosage, route, and site(s).
• Provide a written record to individuals who receive any immune globulin product.
• Regarding RabIg and the administration of live vaccines see Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella or Varicella Virus.
Human Rabies Immune Globulin (RabIg)
HyperRAB®
Supplier: Grifols Canada Inc.

ADVERSE EVENTS:
Local: soreness.
Systemic: fever.

A potential increased risk of thrombosis (blood clots) has been observed within 24 hours of receipt of immune globulin products, especially when given in large doses (i.e., more than 10 mL). Additional risk factors include: age 45 years and older, history of thrombosis or those with risk factors for thrombosis (e.g., obesity, high blood pressure, diabetes, prolonged periods of immobilization, use of estrogens, a history of heart disease, blood clotting disorders, indwelling central vascular catheters, or diseases that thicken the blood). A, B